Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349645 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee
A Phase 3 study, sponsored by Ampio Pharmaceuticals..
- Terminated
- Registry status
- Phase 3
- Development phase
- 94
- Enrollment target
NCT03349645 is a Phase 3 study that was terminated before completion, run by Ampio Pharmaceuticals.. The registered enrollment target is 94 participants.
The verdict
NCT03349645, a Phase 3 study, was terminated before completion, sponsored by Ampio Pharmaceuticals..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 94 participants
- Enrollment target
Study Summary
This Open Label Extension (OLE) study will assess the safety of long-term treatment with a 4 mL intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee
Interventions
- BIOLOGICAL 4 mL injection of AMPION™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2018-10-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03349645
The ClinicalTrials.gov registry entry for NCT03349645 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampio Pharmaceuticals., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 4 mL injection of AMPION™ is the first listed.
NCT03349645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03349645 about?
NCT03349645 is a clinical study titled "Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee". This Open Label Extension (OLE) study will assess the safety of long-term treatment with a 4 mL intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee
What is the current status of trial NCT03349645?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 94 participants. The study started on 2017-12-08. Estimated completion is 2018-10-04.
What interventions are being tested in trial NCT03349645?
The interventions under investigation include: 4 mL injection of AMPION™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT03349645?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.